Fragment 176-191, a modified AOD 9604 peptide, is a human growth hormone fragment. The 176th to the 191st aminos are separated from the chain, with one more amino acid (Tyrosine) added to the fragment. This growth hormone peptide (HGH) fragment has displayed potential in fat loss, a role linked to HGH for the first time in the late 1950s.
HGH fragment 176-191 is frequently considered an imitation of HGH’s C-terminal. It is a peptide containing the last sixteen aminos that reside in the hormone’s sequence. This HGH area has been associated with weight loss and reduced fatty tissue in animals, which takes place through the slowing of lipogenesis and stimulation of lipolysis . This fragment, however, has also been linked to insulin restriction and has therefore raised the risks for hyperglycemia.
This impact could be associated with amino acids 176 to 191 in the sequence of human growth hormone. Contrarily, the HGH amino-terminus has presented a major impact on the breakdown of glucose, arbitrated by insulin in healthy rodents. In vivo studies on animals exploring the HGH fragment properties have found that the fragment may disturb glycogen synthase management, which can cause changes in circulating glucose levels.
With the addition of amino acid 176, the fragment becomes a growth-hormone releasing factor (GRF) analog. This peptide, then, is considered a GH releasing hormone, and may function partly as a growth hormone release regulator as well. GH doesn’t typically exhibit an adverse impact on insulin’s effects, indicating, therefore, that the breakdown of glucose may be boosted by the protein sequence’s opposite end .
Treatment using HGH’s 176-191 peptide fragment could be linked to glycogen synthase phosphatase inactivation in the muscle tissue of rodents, which may then alters within cells the active glycogen synthase concentration. That’s why, in vivo, shortened versions of growth hormone, such as the HGH fragment, may disturb the normal metabolism of glycogen or glucose.
Fragment 176-191 Peptide Research
Researchers suggest Fragment 176-191 may exhibit an ability to burn fat tissue. Research has indicated that the peptide fragment provides significant, positive effects than its previous version. Findings in clinical and laboratory research suggest that Frag 176-191 encourages fat breakdown, similar to the way growth hormone does, and inhibits the conversion of fatty foods into body fat.
GR factor has been suggested to have an ability to elevate GH plasma levels. Other scientists have stated that long-term administration of growth hormone releasing factor appeared to cause a major rise in progesterone and luteinizing hormone (LH) concentrations in non-human subjects. GH releasing factor could also be linked to dyslipidemia decrease. Dyslipidemia is the impairment of fat metabolism which then causes body fat to accumulate at greater rates. Because of that, various researchers assert that analogs of GRF could be used to improve body composition and boost weight loss in non-human animals.
The releasing factor of Growth hormone, as well as its analogs, appear to work to boost the release of growth hormone from tissues like the pituitary gland, which is why they might also affect the progesterone concentrations and various other hormones. Also, analogs of GRF may have more stability than full GH proteins themselves.
Fragment 176-191 could also be used to explore the presumed functions of either growth hormone or GRF in aging or other processes, as well as the response to altered feeding patterns of non-human subjects. The peptide fragment could also be researched to better understand the managerial axis of GRF, IGF and GH.
GRF might even have a function in pre- and postnatal organism development. And, since GRF is part of a huge family of peptide hormones & similar molecules, an analog of GRF that is both bioactive and stable would make for a great testing substance for research. Growth hormone releasing factor, along with its analogs, are linked to both GH and potentially IGF release. GRF release has, for a long time, been linked to the hypothalamus, though it’s been found in other areas as well. It is because of the possibility that GRF may be found in areas like the gonads and the placenta that various scientists suggest that it may also play a part in fetal development. GRF is also found in leukocytes, which is why it might also play a part in the immune management or the immune response.
Fragment 176-191 and Weight Loss
Studies in rodents that have undergone long-term Fragment 176-191 treatment have proposed that it can activate weight loss, which is directly associated with its ability to breakdown fat, though researchers don’t completely understand why. It’s probable that the fat loss occurs when the peptide sticks to the ß3-A receptors, which are associated with fat burn in the body. Recent studies have suggested that HGH fragment 176-191 may help burn fat in average or overweight animal subjects’ mid abdominal region. This HGH peptide fragment could also be involved in decreased fat tissue storage in rodents, though it isn’t linked to the disintegration of current fat stores. The 16 amino acid chain fragment, in its entirety, appears to imitate the GRF. Analogs of GRF or GH might be linked to decreased fat deposits in animals who are treated with this fragment .
Additional research has suggested this fragment’s potential to raise IGF-1 levels, which conveys the anti-aging effects like the ones from HGH. Also, the additional positive impacts, according to studies, include better sleeping patterns and higher bone density.
Fragment 176-191 Safety Profile
Research hasn’t pointed out any serious adversities, particularly if the peptide is administered properly. However, some of the common side effects include the following:
- Soreness or redness at injection site
- Lethargy or drowsiness
- Headache (in rare cases)
If you are a lab researcher looking to purchase top grade peptides for sale from a reputable source, you can buy Fragment 176 191 by visiting Core Peptides. The peptides available commercially including those available for sale here are strictly for research and laboratory use, and are not approved for personal use or human consumption.
- Wu Z., et al. Antilipogenic action of synthetic C-terminal sequence 176 191 of hgh. Biochemistry and molecular biology international, 1993.
- Mondon C. E., et al. Amino-terminal peptide of gh enhances insulin action in normal rats. Endocrinology, 1988.
- Mangili A., et al. Predictors of Treatment Response to Tesamorelin, a GRF Analog, in HIV-Infected Patients with Excess Abdominal Fat, 2015.
NOTE: The information found on this website and within this article is intended for educational or informational purposes only. Some or all of the content in these articles are not substantiated by a medical professional and may be based on the opinions of the writer who may not be a medical or accredited professional. Not intended for personal use. Please review our Terms and Conditions.
Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.